Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent cardiovascular event did not alter the rate of subsequent major cardiovascular or other serious adverse events. Randomized trials involving...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 373; H. 23; S. 2247 - 2257
Hauptverfasser: Pfeffer, Marc A, Claggett, Brian, Diaz, Rafael, Dickstein, Kenneth, Gerstein, Hertzel C, Køber, Lars V, Lawson, Francesca C, Ping, Lin, Wei, Xiaodan, Lewis, Eldrin F, Maggioni, Aldo P, McMurray, John J.V, Probstfield, Jeffrey L, Riddle, Matthew C, Solomon, Scott D, Tardif, Jean-Claude
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 03.12.2015
Schlagworte:
Acute Coronary Syndrome - complications
Acute Coronary Syndrome - drug therapy
Acute coronary syndromes
Aged
Angina
Angina, Unstable - complications
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Cerebral infarction
Clinical trials
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - mortality
Drug dosages
Drug therapy
Female
GLP-1 receptor agonists
Glucagon
Glucagon-like peptide 1
Glucagon-Like Peptide-1 Receptor - agonists
Glucose
Glycated Hemoglobin A - analysis
Heart diseases
Heart failure
Heart rate
Hemoglobin
Humans
Hypersensitivity
Hypoglycemia
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Kaplan-Meier Estimate
Male
Middle Aged
Morbidity
Mortality
Myocardial infarction
Myocardial Infarction - complications
Pancreas
Pancreatic cancer
Pancreatitis
Peptides - adverse effects
Peptides - therapeutic use
Proportional Hazards Models
Regulatory approval
Treatment Failure
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent cardiovascular event did not alter the rate of subsequent major cardiovascular or other serious adverse events. Randomized trials involving patients with new or established type 2 diabetes have shown that improved glucose control reduces the risk of microvascular complications, 1 – 3 with modest cardiovascular benefits suggested by meta-analyses and extended follow-up of clinical trials. 4 – 7 However, various studies indicate that, despite being effective in lowering the glucose and glycated hemoglobin levels, some hypoglycemic medications may increase, rather than reduce, the risk of cardiovascular events. 8 – 10 These unexpected findings prompted the reexamination of the regulatory approval processes for new antidiabetic therapies, which had been based primarily on the surrogate measure of glucose lowering with limited clinical-outcomes data. Since . . .
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1509225